Login to Your Account



Intarcia's exenatide pump outperforms Januvia in phase III

By Michael Fitzhugh
Staff Writer

Wednesday, August 19, 2015

A head-to-head study pitting an implantable exenatide-filled osmotic pump developed by Intarcia Therapeutics Inc. against the blockbuster Januvia over a year of type 2 diabetes treatment proved the pump superior in reducing HbA1c levels and producing weight loss.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription